Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
A PHASE 2a, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATING STUDY
TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICALLY APPLIED BISPHOSPHOCIN NU-3 GEL TO
CLINICALLY NONINFECTED CHRONIC DIABETIC FOOT ULCERS (cDFU)
Phase:
Phase 2
Details
Lead Sponsor:
Lakewood-Amedex Inc
Collaborators:
PrimeVigilance Professional Education and Research Institute